Agenus Inc. (NASDAQ:AGEN) Given Average Recommendation of “Hold” by Brokerages

Agenus Inc. (NASDAQ:AGEN) has received a consensus rating of “Hold” from the six research firms that are covering the stock, Marketbeat.com reports. Five equities research analysts have rated the stock with a hold recommendation and one has given a buy recommendation to the company. The average twelve-month target price among brokers that have covered the stock in the last year is $9.00.

A number of equities research analysts have recently commented on the stock. Robert W. Baird increased their target price on shares of Agenus from $3.00 to $4.00 and gave the company a “neutral” rating in a research report on Tuesday, May 13th. StockNews.com upgraded shares of Agenus from a “sell” rating to a “hold” rating in a research note on Friday, March 21st. B. Riley reissued a “buy” rating on shares of Agenus in a research report on Monday, April 21st. Finally, HC Wainwright reiterated a “neutral” rating on shares of Agenus in a research note on Tuesday, May 13th.

Agenus Trading Up 8.9%

Agenus stock opened at $3.79 on Thursday. The firm has a market capitalization of $103.91 million, a PE ratio of -0.34 and a beta of 1.48. Agenus has a 12-month low of $1.38 and a 12-month high of $19.69. The firm has a 50-day moving average price of $2.28 and a 200-day moving average price of $2.88.

Agenus (NASDAQ:AGEN) last issued its quarterly earnings results on Monday, May 12th. The biotechnology company reported ($1.03) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.61) by $0.58. The company had revenue of $24.07 million for the quarter, compared to analyst estimates of $26.38 million. As a group, sell-side analysts predict that Agenus will post -12.55 earnings per share for the current fiscal year.

Institutional Trading of Agenus

Several institutional investors have recently made changes to their positions in the stock. Corton Capital Inc. bought a new position in Agenus during the fourth quarter worth $36,000. Virtu Financial LLC bought a new stake in shares of Agenus in the 4th quarter valued at about $51,000. Apollon Wealth Management LLC bought a new stake in shares of Agenus in the 4th quarter valued at about $55,000. Bank of Montreal Can bought a new stake in Agenus during the 4th quarter worth approximately $69,000. Finally, Barclays PLC grew its stake in shares of Agenus by 295.3% during the 3rd quarter. Barclays PLC now owns 27,813 shares of the biotechnology company’s stock worth $152,000 after acquiring an additional 20,777 shares in the last quarter. 61.46% of the stock is currently owned by institutional investors and hedge funds.

Agenus Company Profile

Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.